The company plans to name snack food executive Jon Halvorson as it faces a crisis over concerns of links between Tylenol and autism.

Kenvue (NYSE:KVUE), the consumer healthcare spin-off from Johnson & Johnson, has experienced a significant decline in its stock price in recent months.

Texas Attorney General Ken Paxton is suing the makers of Tylenol over allegedly deceptively marketing the over-the-counter drug to pregnant women.

Texas Attorney General Ken Paxton filed the lawsuit saying that the companies had knowingly hidden the risks of Tylenol, which he said is related to autism and attention deficit hyperactivity disorder.

Kenvue Inc. (NYSE: KVUE) will announce its third quarter 2025 financial results before the market opens on November 6, 2025.

Paxton said that Johnson & Johnson violated Texas’ consumer protection laws by marketing the drug as a safe pain medication for pregnant women.

A potential legal headache for consumer healthcare giant Kenvue ( KVUE 8.36%) was causing pain for investors on Thursday. Such troubles tend to spook the market; hence the more than 13% sell-off of Kenvue across that trading session. The S&P 500 ( ^GSPC 0.53%), by comparison, did much better on the day with "only" a 0.6% decrease.